Amanda Lusk

Amanda Lusk supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing strategic procurement activities critical to advancing regulatory science and sustaining high-precision laboratory infrastructure. She manages a diverse portfolio of acquisitions focused on scientific support services, analytical instrumentation, and specialized research consulting, ensuring the FDA maintains the technical capabilities necessary to evaluate drug safety, efficacy, and medical device performance. Her work directly enables mission-critical functions including toxicology studies, clinical research support, and laboratory operations, aligning procurement decisions with the agency’s public health mandate. Lusk regularly collaborates with niche scientific contractors including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., forming long-term partnerships with firms specializing in preclinical research, pathology analysis, and pharmaceutical development support. These relationships reflect a preference for vendors with deep domain expertise in FDA-regulated environments, emphasizing technical proficiency, regulatory compliance, and validated methodologies. Her contracting approach prioritizes performance-based outcomes and scientific rigor over broad commercial solutions. Her procurement patterns show a balanced approach to socioeconomic goals, with approximately one-third of awards competed under the 8(a) program, demonstrating a deliberate commitment to small business participation. The majority of contracts are awarded without set-aside, indicating a focus on technical capability and mission alignment over socioeconomic categorization alone. This reflects a pragmatic blend of regulatory necessity and small business outreach. Lusk’s primary procurement focus lies in NAICS 561621 (security systems services), 541611 (management consulting), and 334516 (analytical laboratory instrument manufacturing), underscoring her expertise in securing specialized services for laboratory security, scientific operations management, and high-end instrumentation. She consistently procures services supporting toxicology, clinical trial support, and analytical validation, reinforcing the FDA’s reliance on precision science to safeguard public health.